THE PATH TO INNOVATING DIABETES CARE IN TURKEY

7.2 MILLION
PEOPLE HAVE DIABETES IN TURKEY

HIGH HbA$_1$C
THE AVERAGE LEVEL IS 10.6%

60% OF PATIENTS HAVE AT LEAST ONE COMPLICATION

23% OF TOTAL HEALTH EXPENDITURES IS ON DIABETES

74% OF TOTAL COST OF DIABETES IS RELATED TO COMPLICATIONS

WE INVEST IN LOCAL R&D CAPABILITIES
97% of physicians believe that conducting clinical trials is beneficial for patient outcomes. Over the last ten years, we have conducted one-third of all clinical trials on diabetes in Turkey.

WE ADVOCATE FOR INNOVATION TO MEET PATIENT NEEDS
Innovation in treatment and care helps meet patient needs. Recently we hosted and supported an International Diabetes Leadership Forum and an Innovation Roundtable in Turkey.

WE BUILD DIABETES CARE CAPABILITIES
Together with the Turkish Ministry of Health and other partners, the Turkish Diabetes Control Project has enabled countrywide training for healthcare professionals.

WE HELP PEOPLE WITH DIABETES TAKE BETTER CARE OF THEMSELVES
Proper self-management is essential for reaching treatment targets. We support projects that enable people with diabetes to bring knowledge to rural communities as peer educators.

LOWERING HbA$_1$C LEVELS IS KEY
TO REDUCE THE RISK OF COMPLICATIONS

10.6% ≤ 7%

24 billion euros could be saved between now and 2035 if the average HbA$_1$C level is reduced to that of treatment guidelines.

Reducing HbA$_1$C levels within one year of diagnosis to 7%, can extend life without diabetes complications by up to 6.5 years.

Today, we provide diabetes care products to more than 530,000 people in Turkey.

For each job in clinical research, six additional jobs are created in the surrounding economy.

TOGETHER, WE CAN ACHIEVE EVEN MORE

FOR REFERENCES AND THE FULL STUDY, PLEASE VISIT novonordisk.com/blueprint